UTRS vs. NYXH, STVN, SYK, BSX, BDX, MMM, DXCM, RMD, WST, and BAX
Should you be buying Minerva Surgical stock or one of its competitors? The main competitors of Minerva Surgical include Nyxoah (NYXH), Stevanato Group (STVN), Stryker (SYK), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), 3M (MMM), DexCom (DXCM), ResMed (RMD), West Pharmaceutical Services (WST), and Baxter International (BAX). These companies are all part of the "surgical & medical instruments" industry.
Minerva Surgical (NASDAQ:UTRS) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, community ranking, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Nyxoah has a consensus price target of $19.40, suggesting a potential upside of 106.16%. Given Nyxoah's higher possible upside, analysts plainly believe Nyxoah is more favorable than Minerva Surgical.
In the previous week, Nyxoah had 5 more articles in the media than Minerva Surgical. MarketBeat recorded 5 mentions for Nyxoah and 0 mentions for Minerva Surgical. Nyxoah's average media sentiment score of 0.47 beat Minerva Surgical's score of 0.00 indicating that Nyxoah is being referred to more favorably in the news media.
Minerva Surgical has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.
Minerva Surgical has a net margin of -64.71% compared to Nyxoah's net margin of -843.49%. Nyxoah's return on equity of -42.14% beat Minerva Surgical's return on equity.
Minerva Surgical has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
Nyxoah received 23 more outperform votes than Minerva Surgical when rated by MarketBeat users. Likewise, 66.67% of users gave Nyxoah an outperform vote while only 41.18% of users gave Minerva Surgical an outperform vote.
Summary
Nyxoah beats Minerva Surgical on 11 of the 15 factors compared between the two stocks.
Get Minerva Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Minerva Surgical Competitors List
Related Companies and Tools
